Early Clinical Experience with the ALPFA GRAIL System for the Minimally Invasive Treatment of Benign Prostatic Hyperplasia
AUA Annual meeting (May 15, 2026)
S. Secco
Pulsed Field Ablation Selectively Spares the Oesophagus During Pulmonary Vein Isolation for Atrial Fibrillation.
Europace (2021)
H. Cochet et al.
Key insight: Demonstrates PFA's non-thermal mechanism preserves critical adjacent structures—directly relevant to protecting nerves/vessels in prostate applications.
Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.
New England Journal of Medicine (2023)
V. Y. Reddy et al.
Key insight: Head-to-head superiority/safety data establishing PFA as a game-changer vs. thermal methods.
Pulsed Field Ablation versus Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: 4-Year Outcomes in the ADVENT-LTO Study.
Nature Medicine (2026)
V.Y. Reddy et al.
Key insight: Sustained outcomes reinforcing durability of PFA lesions—foundational for ALPFA's elasticity restoration goals.
Real-World Experience with the Pentaspline Pulsed Field Ablation System: One-Year Outcomes of the FARADISE Registry.
Europace (2025)
L.V.A. Boersma et al.
Key insight: Large-scale, multi-center data on safety and effectiveness in everyday practice.
State-of-the-Art Pulsed Field Ablation for Cardiac Arrhythmias: Ongoing Evolution and Future Perspective.
Europace (2024)
K.-R. J. Chun et al.
Key insight: Broad overview of PFA evolution, ideal for contextualizing ALPFA's urologic application.
